Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (GB:0JXI)
LSE:0JXI
RESEARCH TOOLSreports
Holding GB:0JXI?
Track your performance easily
0JXI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$168.17 - $363.57
Previous Close$300.14
Volume45.00
Average Volume (3M)281.00
Market Cap
$6.40B
Enterprise Value$5.52B
Total Cash (Recent Filing)$998.63M
Total Debt (Recent Filing)$119.14M
Price to Earnings (P/E)―
Beta2.88
Next Earnings
Feb 26, 2025EPS Estimate
-$4.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.07
Shares Outstanding21,810,407
10 Day Avg. Volume126
30 Day Avg. Volume281
Standard Deviation0.43
R-Squared0.00001
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)8.76
Price to Sales (P/S)83.31
Price to Cash Flow (P/CF)-23.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue71.86
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-14.05
Forecast
1Y Price Target
$377.45Price Target Upside25.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Madrigal Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentCompletion of patient enrollment in the Phase III MAESTRO-NASH OUTCOMES study exceeded initial targets, showcasing strong advancement in clinical development.
EarningsStrong revenues of $62.2M significantly surpassed expectations, boosting investor confidence in the company's launch execution and demand for NASH therapeutics.
Market PenetrationAchieved coverage for over 80% of commercial lives, indicating substantial improvement and market acceptance compared to previous quarters.
Bears Say
Competitive PressureAnticipated competitive pressure from GLP-1-based therapies could impact future market penetration of Rezdiffra.
Regulatory ChallengesFailure to obtain FDA or EMA approvals presents a significant risk.
Reimbursement HurdlesThe difficult reimbursement process, requiring proof of diagnosis and taking weeks for the first dose, poses a challenge.
---
0JXI FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest share price was $168.17 and its highest was $363.57 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Feb 26, 2025 which is in 67 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Oct 31, 2024. The company reported -$4.92 earnings per share for the quarter, beating the consensus estimate of -$6.748 by $1.828.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -$4.51.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 21,810,408 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$4.92 in its last earnings report, beating expectations of -$6.748. Following the earnings report the stock price went up 20.94%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Among the largest hedge funds holding Madrigal Pharmaceuticals Inc’s share is Paulson & Co Inc. It holds Madrigal Pharmaceuticals Inc’s shares valued at 433M.
---
Madrigal Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$377.45 (25.76% Upside)
$377.45 (25.76% Upside)
Blogger Sentiment
Bullish
GB:0JXI Sentiment 92%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.54%
12-Months-Change
Fundamentals
Return on Equity
-129.76%
Trailing 12-Months
Asset Growth
351.02%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
---
0JXI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong and promising launch of Rezdiffra with significant achievements in sales, coverage, and prescriber penetration. However, increased operational expenses and future uncertainties in gross-to-net adjustments present challenges. Overall, the sentiment is optimistic with a cautious outlook on future financial dynamics.Read More>---
0JXI Stock 12 Month Forecast
Average Price Target
$377.45
▲(25.76% Upside)
Technical Analysis
Madrigal Pharmaceuticals
―
Viking Therapeutics
―
Arrowhead Pharmaceuticals
―
Alnylam Pharma
―
Galectin Therapeutics
―
Best Analysts Covering 0JXI
1 Year
1 Year Success Rate
15/21 ratings generated profit
1 Year Average Return
+92.70%
reiterated a buy rating 5 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +92.70% per trade.
---